← SynDRA
DEFACTINIB
SynDRA canonical compound SYN0037861 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PTK2 |
|---|
| Mechanism of action | Focal adhesion kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- FAK inhibitor
- PTK2 INHIBITOR
- Focal adhesion kinase 1 inhibitor
- PTK2B INHIBITOR
- Protein tyrosine kinase 2 beta inhibitor
- LATS1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NUAK2
- STK16
- JAK2
- DMPK
- AURKA
- AURKB
- CDK2
- MAP3K11
- FLT3
- RET
- NTRK3
- NTRK2
- NTRK1
- TAOK3
- TAOK1
- TNK1
- SYK
- CDK13
- CDK12
- STK4
- STK17A
- CDK1
- GSK3A
- CSNK2A2
- GSK3B
- PIK3CA
- KDR
- STK3
- DRD1
- MAP3K19
- CDK5
- TYK2
- MARK1
- MARK2
- MARK3
- PAK4
- CLK1
- CLK2
- SLK
- WEE1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CCNA1
- CCNA2
- CP2C9
- CP3A7
- HLAB
- IFNB1
- IFNG
- KSYK
- NSD2
- SNCA
- SYUA
- TP53
Cross-references
Synonyms
- AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
- Fakzynja
- VS-6063
- DEFACITINIB
- DEFACTINIB (VS-6063)
- Defactinib hydrochloride
- PF-04554878
- PF 04554878
- VS 6063
- Defactinib (VS-6063, PF-04554878)
- 53O87HA2QU
- VS6063
- Defactinib [USAN:INN]
- UNII-53O87HA2QU
- Defactinib [USAN]
- DEFACTINIB [INN]
- Defactinib (USAN/INN)
- DEFACTINIB [WHO-DD]
- GTPL7910
- SCHEMBL1627234
- CHEMBL3137331
- BDBM418817
- DTXSID901025937
- HMS3740O13
- AMY42170
- BCP11299
- EX-A1037
- EX-A1049
- MFCD25977806
- NSC778364
- NSC781450
- NSC782549
- NSC800089
- s7654
- US10450297, Example 317
- US10450297, Example 318
- AKOS026750300
- ZINC103297739
Look up DEFACTINIB in the interactive SynDRA portal →